Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 27

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 27
---
 any strategic transactions that will provide the capital that SKNY will require or achieve the other strategies to alleviate the conditions that raise substantial doubt about SKNY’s ability to continue as a going concern. The failure to obtain sufficient capital on acceptable terms when needed may require SKNY to delay, limit, or eliminate the development of business opportunities and SKNY’s ability to achieve its business objectives. Any of such failures will materially adversely affect SKNY’s competitiveness, and SKNY’s business, financial condition, and results of operations. In addition, the perception that SKNY may not be able to continue as a going concern may cause others to choose not to deal with it due to concerns about SKNY’s ability to meet SKNY’s contractual obligations.

SKNY has significant and increasing liquidity needs and will require additional funding.

Research and development, general and administrative expenses and cash used for operations will continue to be significant and may increase substantially in the future in connection with new research and development initiatives and continued product commercialization efforts. Following the Merger, the combined company may need to raise additional capital to fund its operations, continue clinical trials to support potential regulatory approval of marketing applications and to fund commercialization of its products.

Operating results may vary significantly in future periods.

Following the Merger, the combine company’s operating and financial results are likely to fluctuate significantly in the future. SKNY’s operating and financial results are unpredictable and may fluctuate, for among other reasons, due to:

| ● | SKNY’s                                                                      
 achievement of product development objectives and milestones                |
| ● | clinical                                                                    
 trial enrollment and expenses;                                              |
| ● | research                                                                    
 and development expenses; and                                               |
| ● | the                                                                         
 timing and nature of contract manufacturing and contract research payments. |

In addition, a high portion of SKNY’s costs are determined on an annual basis, due in part to SKNY’s significant research and development costs. Thus, increases in SKNY’s costs could disproportionately affect financial results in a quarter. Other factors, including non-cash expenses associated with financing activity, could also lead to fluctuations in SKNY’s results of operations. Because of these factors, SKNY’s operating and financial results in one or more future quarters may fail to meet the expectations of securities analysts or investors, which could cause MIRA’s share price to decline.

| 12 |

SKNY has yet to generate revenues or achieve a profit and may not generate revenue or achieve a profit for many years, if at all.

SKNY has not yet produced any revenues or profit